Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IL18 | Q14116 | 1/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047 | 0.87 | EGFR (0.52) | KDM4ELMNAMAPTMEN1KMT2A | |
| Water SCHEMBL29120229 | 0.87 | EGFR (0.52) | KDM4ELMNAMAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28598774 | 0.85 | EGFR (0.50) | KDM4ELMNAMAPTMEN1KMT2A | |
| SCHEMBL20032249 | 0.83 | PARP15 (0.52) | PARP10PARP15PARP2KDM4ELMNA | |
| SCHEMBL10064744 | 0.83 | PARP15 (0.52) | PARP10PARP15PARP2KDM4ELMNA | |
| SCHEMBL4104432 | 0.83 | CYP19A1 (0.47) | PARP10PARP15PARP2KDM4ELMNA | |
| SCHEMBL3163442 | 0.83 | PGR (0.47) | PARP10KDM4ELMNAPARP3CYP19A1 | |
| SCHEMBL1663469 | 0.82 | PARP10 (0.65) | PARP10KDM4ELMNAMAPTPOLB | |
| SCHEMBL7041250 | 0.82 | PARP15 (0.63) | PARP10PARP15PARP2KDM4ELMNA | |
| SCHEMBL5050902 | 0.82 | PARP10 (0.65) | PARP10KDM4ELMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38425-E1 | ANTICONVULSANTS ADMINISTERED ORALLLY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC. (CA) | 2004-02-10 | — | — | US | claimed |
| EP-0836591-B1 | SEMICARBAZONES HAVING CNS ACTIVITY AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | UNIV SASKATCHEWAN (CA) | 2001-09-26 | — | — | EP | claimed |
| US-5741818-A | ANTICONVULSANTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-04-21 | — | — | US | claimed |
| WO-2024189504-A1 | BROAD - SPECTRUM ANTI VIRAL COMPOUNDS | FOUNDATION FOR NEGLECTED DISEASE RESEARCH (IN) | 2024-09-19 | — | — | WO | disclosed |
| EP-3544972-B1 | HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS | PFIZER (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-110234638-B | Heteroaryl phenoxy benzamide KAPPA opioid ligands | 辉瑞大药厂 | 2022-10-21 | — | — | CN | disclosed |
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| CN-109111451-B | Dihydropyrimidine compound and application thereof in medicine | 广东东阳光药业有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (CN) | 2020-04-16 | — | — | US | disclosed |
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (CN) | 2020-04-16 | — | — | US | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1435947-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040091530-A1 | Dosage forms for oral admistration resulting in a maximum secretagogue plasma concentration, Cmax, less than 80% Cmax of that when an equal dose is administered in an immediate release form; osmotic tablet of a asymetric membrane; 6 hours | AM ENDE MARY T (US) | 2004-05-13 | — | — | US | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003032984-A1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES AS CDSI/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | DPYD, SLC10A1, DHODH | PARP10 3483/4885PARP15 2534/4885PARP2 3081/4885 |
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | DPYD, SLC10A1, DHODH | PARP10 3483/4885PARP15 2534/4885PARP2 3081/4885 |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, TMBIM6, CDS2 | PARP10 3236/4885PARP15 2231/4885PARP2 2027/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | PARP10 2434/4885PARP15 4274/4885PARP2 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.